Trials / Conditions / Angioplasty, Transluminal, Percutaneous Coronary

Angioplasty, Transluminal, Percutaneous Coronary

29 registered clinical trials studyying Angioplasty, Transluminal, Percutaneous Coronary — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions NCT07316504	University Hospital, Clermont-Ferrand	N/A
Unknown	Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI P NCT03047772	Yuejin Yang	Phase 2
Unknown	Randomized Comparison of Radiological Exposure With TRIPTable® in Patients With Acute Coronary Syndromes NCT02200783	Marilia Medicine School	N/A
Terminated	DESyne in Routine Clinical Practice NCT02039713	Seung-Jung Park	—
Completed	Orsiro™ Drug Eluting Stent in Routine Clinical Practice NCT02039739	Seung-Jung Park	—
Completed	Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions NCT01241903	Susan Smyth	Phase 1
Unknown	To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study NCT00870038	Ospedale della Misericordia	Phase 4
Unknown	Strategies of Revascularization in Patients With ST-segment Elevation Myocardial Infarction (STEMI) and Multiv NCT01179126	Complexo Hospitalario Universitario de A Coruña	Phase 3
Completed	Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery D NCT01004575	Terumo Europe N.V.	N/A
Completed	Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY) NCT01174433	University of Padova	Phase 1 / Phase 2
Unknown	Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention NCT00938522	Samsung Medical Center	Phase 4
Completed	Left Versus Right Transradial Approach for Percutaneous Coronary Procedures NCT00821106	Policlinico Casilino ASL RMB	N/A
Completed	Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarct NCT00979758	Chinese Academy of Medical Sciences, Fuwai Hospital	Phase 2
Unknown	European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent NCT00637104	International Biomedical Systems S.p.A.	Phase 2 / Phase 3
Completed	Plug Arterial Closure System (PACS, 7F) NCT00533156	Cordis US Corp.	Phase 2
Completed	Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention NCT00610870	Samsung Medical Center	N/A
Completed	ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis Trial) EU NCT00574691	Cordis US Corp.	Phase 1
Completed	Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device NCT00345631	Cordis US Corp.	Phase 3
Completed	Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3) NCT00390832	Deutsches Herzzentrum Muenchen	Phase 3
Unknown	Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial NCT00500279	Seoul National University Hospital	Phase 4
Completed	Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST) NCT00390585	Deutsches Herzzentrum Muenchen	Phase 4
Completed	Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance NCT00398463	Università degli Studi di Ferrara	Phase 4
Completed	Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography NCT00345501	Onassis Cardiac Surgery Centre	Phase 2 / Phase 3
Completed	The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Corona NCT00133731	Sanofi	Phase 2
Completed	Arterial Access for Coronary Intervention in Myocardial Infarction NCT00356044	Hospital Juan Canalejo	Phase 4
Completed	A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platele NCT00271401	Centocor, Inc.	Phase 3
Completed	A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Diff NCT00269880	Centocor, Inc.	Phase 3
Completed	A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable A NCT00269906	Centocor, Inc.	Phase 3
Completed	A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High NCT00269893	Centocor, Inc.	Phase 3